Screen Reader Access

Naibedya Chattopadhyay, Ph.D.

Chief Scientist, Endocrinology

I direct the Centre for Research in Anabolic Skeletal
Targets in Health and Illness (ASTHI)

C.S.I.R-C.D.R.I

Salient Achievements of the ASTHI Program

CDRI's Centre of Excellence: Centre for Research on Anabolic Skeletal Targets in Health and Illness

A Glimpse of Phytopharmaceutic Research at the ASTHI Centre

ASTHI Webinar Series

2022 - List of Publications from ASTHI Program^New

I direct the Centre for Research in Anabolic Skeletal Targets in Health and Illness (ASTHI) funded by CSIR since 2012. Centre ASTHI, dedicated to research in bone biology and metabolic bone disease, is first and only-of-its-kind in the country. The overall goal of the centre is to foster interdisciplinary and collaborative work that would lead to a deeper understanding of skeletal biology, in a way that would lead to new ways of diagnosing and treating skeletal diseases.Broad objectives of the centre are;

Application of novel approaches to understand the processes underlying biomineralization of bone tissue, which is translatable to therapeutics in future

To understand the physiology of bone anabolism at modeling and remodeling stages using state-of-the-art genetic engineering in mice, which would provide a fresh paradigm in the understanding of the pathophysilogy of postmenopausal osteoporosis

Engineering a novel system for augmented deliverance of experimental therapeutics with bone anabolic effect.

Education

1985-B.Sc. Presidency College, Calcutta University (Hons. Physiology)
1988-M.Sc. Presidency College, Calcutta University (Physiology)
1993-Ph.D. Sanjay Gandhi Post-Graduate Institute of Medical Sciences, (Endocrinology) Lucknow, India

1985-B.Sc. Presidency College, Calcutta University (Hons. Physiology)

1988-M.Sc. Presidency College, Calcutta University (Physiology)

1993-Ph.D. Sanjay Gandhi Post-Graduate Institute of Medical Sciences, (Endocrinology) Lucknow, India

Postdoc

1994 -1998 Post doctoral research fellow, Endocrine-Hypertension Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

1994 -1998 Post doctoral research fellow, Endocrine-Hypertension Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Positions

11/1998- 06/2003 Instructor in Medicine, Harvard Medical School, Endocrine-Hypertension Division, Brigham and Women’s Hospital, Boston, MA.
07/2003-04/2006 Assistant Professor of Medicine, Harvard Medical School, Division of Endocrinology, Diabetes & Hypertension, Brigham and Women’s Hospital, Boston, MA.
04/2006-04/2011 Senior Principal Scientist and Head, Endocrinology CSIR-CDRI
05/2011 - Chief Scientist, Division of Endocrinology, CSIR- Central Drug Research Institute, Lucknow
Professor of Biological Sciences, Academy of Scientific and Innovative Research, Council of Scientific and Industrial Research (CSIR), Ministry of Science & Technology, Government of India

11/1998- 06/2003 Instructor in Medicine, Harvard Medical School, Endocrine-Hypertension Division, Brigham and Women’s Hospital, Boston, MA.

07/2003-04/2006 Assistant Professor of Medicine, Harvard Medical School, Division of Endocrinology, Diabetes & Hypertension, Brigham and Women’s Hospital, Boston, MA.

04/2006-04/2011 Senior Principal Scientist and Head, Endocrinology CSIR-CDRI

05/2011 - Chief Scientist, Division of Endocrinology, CSIR- Central Drug Research Institute, Lucknow

Professor of Biological Sciences, Academy of Scientific and Innovative Research, Council of Scientific and Industrial Research (CSIR), Ministry of Science & Technology, Government of India

Contact Details

Email id: n_chattopadhyay[AT]cdri.res.in

Tel: 0522-2772450 EPABX-4967

Selected Publications

1. Sharan K, Swarnkar G, Siddiqui JA, Khan K, Kumari R, Rawat P, Maurya R, Sanyal S, Chattopadhyay N. A novel quercetin analog from a medicinal plant promotes peak bone mass achievement, bone healing after injury and exerts anabolic effect on osteoporotic bone: the role of aryl hydrocarbon receptor as a mediator of osteogenic action. J Bone Miner Res 26:2096-2111, 2011.

2. Swarnkar G, Sharan K, Siddiqui JA, Mishra JS, Khan K, Khan MP, Gupta V, Rawat P, Maurya R, Dwivedi AK, Sanyal S, Chattopadhyay N. Identification of a rare naringenin analog from a medicinal plant having potent bone anabolic effect by acting as an osteoblast oestrogen mimic. Br J Pharmacol 165:1526-42, 2012.

3. Tripathi JK, Pal S, Awasthi B, Kumar A, Tandon A, Mitra K, Chattopadhyay N*, Ghosh JK. Variants of Self-assembling peptide, KLD-12 that show both rapid fracture healing and antimicrobial properties. Biomaterials 56:92-103, 2015. *Co-corresponding author.

4. Khan MP, Singh AK, Joharapurkar AA, Yadav M, Shree S, Kumar H, Gurjar A, Mishra JS, Tiwari MC, Nagar GK, Kumar S, Ramachandran R, Sharan A, Jain MR, Trivedi AK, Maurya R, Godbole MM, Gayen JR, Sanyal S, Chattopadhyay N. Pathophysiological mechanism of bone loss in type 2 diabetes involves inverse regulation of osteoblast function by PPAR? coactivator-1a and skeletal muscle atrogenes: adiponectin receptor 1 as a potential target for reversing diabetes-induced osteopenia. Diabetes 64: 2609-23, 2015.

5. Pal, Sayeed M, Kumar A, Verma DP, Harioudh MK, Verma NK, Porwal K, Sharma S, Kulkarni C, Bandyopadhyay A, Mugale MN, Mitra K, Ghosh JK, Chattopadhyay N. A self-assembling nano-globular peptide from human lactoferrin acts as a systemic enhancer of bone regeneration: a novel peptide for orthopedic application. ACS Appl Mater Interfaces 13: 17300-17315, 2021 .

For Full Publications
https://orcid.org/0000-0003-2473-0246

For Patents see the link
https://patents.justia.com/inventor/
naibedya-chattopadhyay

Awards & Fellowships

Research Group

View All...